(generic name, trastuzumab): A drug used to treat advanced breast cancer patients whose tumors over-express the HER2 growth factor. See also HER2 or HER-2/neu.
A humanized monoclonal antibody to the HER-2 growth factor receptor intended for use in the treatment of HER-2 overexpressing metastatic breast cancer. Indication: for treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 protein and who have received one or more chemotherapy regimens for their metastatic disease; administration in combination with paclitaxel (Taxol®) for the treatment of patients with metastatic breast cancer whose tumors overexpress HER-2 protein and who have not received chemotherapy for their metastatic disease. Administration: weekly via intravenous infusion. Mfg: Genentech, Inc. Source: Business Wire - 03/31/98; HHS (Health and Human Services) news - 09/25/98.
commercial name for an antibody that attaches itself to HER2 on breast cancer tumors, inhibiting the tumor's ability to grow. Approximately 15 - 25 % of breast cancer patients have a gene mutation known as HER2-positive.
the trade name for trastuzumab
is a humanized antibody that binds to the HER2/neu cancer associated antigen to treat breast cancer.
A medical agent indicated for the treatment of certain breast cancer patients. Herceptin® injection can cause fatal pulmonary effects in patients with preexisting lung conditions.
One of a biological class of drugs known as monoclonal antibodies. Treatment for women with advanced breast cancer who overexpress HER2/neu.
Also called trastuzumab. A cancer treatment that uses antibodies. It is mainly used to treat women with advanced breast cancer. When the cancer has come back or has spread to other parts of the body, The drug works by sticking to a specific protein called HER2 found on the surface of some breast cancer cells. This causes the cancer cells to stop growing. Unfortunately, HER2 is only found on about a fifth of breast cancers, so not all patients can benefit from Herceptin. The drug may be given as a treatment on its own or together with certain chemotherapy drugs. It is being used in trials to see whether it can reduce the chance of breast cancer returning, following initial treatment.
A medicine used in the treatment of breast cancer.
A monoclonal antibody used to treat breast cancer that is estrogen-receptor positive and has spread after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Herceptin binds to HER-2, a human epidermal growth factor receptor, and can kill HER-2 positive cancer cells. Also called trastuzumab.
herceptin is designed to block a protein receptor called her2 that is produced in excess amounts in some women with breast cancer. first monoclonal antibody to fight metastatic breast cancer, to slow the progression of cancer and causes tumor shrinkage.
A type of monoclonal antibody used to detect or treat some types of cancer. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. Herceptin blocks the effects of the growth factor protein HER2, which transmits growth signals to breast cancer cells. Also called trastuzumab.
A monoclonal antibody designed to destroy breast cancer cells which over express an abnormal oncogene called HER2.